Carregant...

Ixazomib: An Oral Proteasome Inhibitor for the Treatment of Multiple Myeloma

The FDA approval of ixazomib for use in combination with lenalidomide and dexamethasone for patients with multiple myeloma who have received at least one prior therapy signalled the arrival of the first oral proteasome inhibitor, allowing advanced practitioners to provide multiple myeloma patients a...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Adv Pract Oncol
Autor principal: Ramirez, Krista G.
Format: Artigo
Idioma:Inglês
Publicat: Harborside Press 2017
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6040877/
https://ncbi.nlm.nih.gov/pubmed/30018846
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!